
RZLT
Healthcare · Biotechnology · $353.5M market cap
$3.65-0.21 (-5.6%)Nov 13, 4:29 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -25.0% over 90 days · 30-day revisions 0 up, 4 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 11, 2027 · upcoming | After the close | -0.17 | — | — |
| Nov 5, 2026 | After the close | -0.18 | -0.18 | 0.0% |
| Sep 24, 2026 | After the close | -0.14 | -0.20 | -42.9% |
| May 13, 2026 | Time not confirmed | -0.17 | -0.16 | +8.0% |
| Feb 12, 2026 | After the close | -0.18 | -0.22 | -22.2% |
| Nov 6, 2025 | After the close | -0.26 | -0.18 | +30.8% |
| Sep 17, 2025 | Time not confirmed | -0.21 | -0.26 | -21.9% |
| May 13, 2025 | After the close | -0.24 | -0.27 | -12.5% |
| Feb 12, 2025 | After the close | -0.26 | -0.22 | +15.4% |
| Nov 7, 2024 | After the close | -0.34 | -0.22 | +35.3% |
| Sep 19, 2024 | After the close | -0.33 | -0.44 | -33.3% |
| May 15, 2024 | After the close | -0.32 | -0.34 | -6.3% |
| Feb 13, 2024 | After the close | -0.29 |
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly…
| -0.27 |
| +6.9% |
| Nov 13, 2023 | After the close | -0.28 | -0.28 | 0.0% |
| Sep 14, 2023 | After the close | -0.36 | -0.25 | +30.6% |
| May 11, 2023 | After the close | -0.30 | -0.30 | 0.0% |
| Feb 10, 2023 | After the close | -0.32 | -0.26 | +18.8% |
| Nov 9, 2022 | After the close | -0.35 | -0.19 | +45.7% |
| Sep 15, 2022 | After the close | -0.41 | -0.37 | +9.8% |
| May 12, 2022 | After the close | -0.97 | -0.65 | +33.0% |
| Feb 9, 2022 | After the close | -0.66 | -0.80 | -21.2% |
| Nov 12, 2021 | After the close | -0.89 | -0.92 | -3.4% |
| Sep 15, 2021 | After the close | -0.80 | -0.78 | +2.5% |
| May 17, 2021 | After the close | -0.78 | -0.66 | +15.4% |
| Feb 10, 2021 | After the close | -0.75 | -0.88 | -17.3% |
| Nov 12, 2020 | After the close | -0.84 | -0.62 | +26.2% |
| Sep 2, 2020 | Time not confirmed | -0.61 | -0.60 | +0.8% |
| May 14, 2020 | After the close | -1.00 | -1.00 | 0.0% |
| Feb 12, 2020 | After the close | -1.00 | -1.00 | 0.0% |
| Nov 14, 2019 | After the close | -1.00 | -1.00 | 0.0% |
| Sep 10, 2019 | Before the open | -1.50 | -2.00 | -33.3% |
| May 10, 2019 | Before the open | — | -0.32 | — |
| Feb 14, 2019 | Before the open | — | -0.07 | — |
| Dec 14, 2018 | Before the open | — | -0.20 | — |
| May 15, 2018 | Before the open | — | -0.09 | — |
| Feb 14, 2018 | Before the open | — | -0.11 | — |